Safety, Pharmacokinetics and Pharmacodynamics of DSP-8658 in Patients With Type 2 Diabetes Mellitus and Healthy Adults
Primary Purpose
Type 2 Diabetes Mellitus
Status
Completed
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
DSP-8658
Placebo
Sponsored by

About this trial
This is an interventional treatment trial for Type 2 Diabetes Mellitus focused on measuring diabetes
Eligibility Criteria
Inclusion Criteria: Diabetic subjects
- Age ≥ 18 and ≤ 65 years
- Body Mass Index ≤45
- Drug naive type 2 diabetes or type 2 diabetes previously treated with an oral antidiabetic drug
Inclusion Criteria: Healthy subjects
- Age ≥ 18 and ≤ 65 years
- Body Mass Index ≥ 18 and ≤ 29
- Good health as determined by medical history, ECG, clinical chemistry, hematology, urinalysis, virology, and a physical examination.
Exclusion Criteria: Diabetic subjects
- Have a current or expected requirement for any antidiabetic or lipid-lowering drug
Exclusion Criteria: Healthy subjects
- Have, or have had a history of clinically significant neurological, urological, gastrointestinal, renal, hepatic, cardiovascular, psychological, pulmonary, metabolic, endocrine, hematological, or other major disorders including cancer
Sites / Locations
- Cetero Research
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Placebo Comparator
Arm Label
DSP-8658
Placebo
Arm Description
DSP-8658 2.5, 10, 20, 40 mg once daily
Placebo 2.5, 10, 20, and 40 mg doses once daily
Outcomes
Primary Outcome Measures
Safety assessments include physical examination, laboratory variables and ECG.
Secondary Outcome Measures
Pharmacokinetics of DSP-8658 and its metabolites: levels of DSP-8658 and its metabolites will be measured and analyzed at various time points throughout the study.
Pharmacodynamics of DSP-8658 (how DSP-8658 acts in the body to affect glucose and lipid control): glucose and lipid levels will be measured at various time points throughout the study.
Full Information
NCT ID
NCT01042106
First Posted
December 21, 2009
Last Updated
September 12, 2013
Sponsor
Sumitomo Pharma America, Inc.
1. Study Identification
Unique Protocol Identification Number
NCT01042106
Brief Title
Safety, Pharmacokinetics and Pharmacodynamics of DSP-8658 in Patients With Type 2 Diabetes Mellitus and Healthy Adults
Official Title
A Randomized, Double-blind, Placebo-controlled, Multiple Ascending Oral Dose Study to Evaulate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of DSP-8658 in Type 2 Diabetic and Healthy Subjects
Study Type
Interventional
2. Study Status
Record Verification Date
September 2013
Overall Recruitment Status
Completed
Study Start Date
November 2009 (undefined)
Primary Completion Date
July 2010 (Actual)
Study Completion Date
July 2010 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Sumitomo Pharma America, Inc.
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple ascending doses of DSP-8658 in patients with Type 2 diabetes mellitus and healthy adults.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type 2 Diabetes Mellitus
Keywords
diabetes
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
40 (Actual)
8. Arms, Groups, and Interventions
Arm Title
DSP-8658
Arm Type
Experimental
Arm Description
DSP-8658 2.5, 10, 20, 40 mg once daily
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Placebo 2.5, 10, 20, and 40 mg doses once daily
Intervention Type
Drug
Intervention Name(s)
DSP-8658
Intervention Description
Ascending doses of DSP-8658 - 2.5, 10, 20, 40 mg orally once daily
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
Placebo 2.5, 10, 20, 40 mg orally once daily
Primary Outcome Measure Information:
Title
Safety assessments include physical examination, laboratory variables and ECG.
Time Frame
20 days
Secondary Outcome Measure Information:
Title
Pharmacokinetics of DSP-8658 and its metabolites: levels of DSP-8658 and its metabolites will be measured and analyzed at various time points throughout the study.
Time Frame
20 days
Title
Pharmacodynamics of DSP-8658 (how DSP-8658 acts in the body to affect glucose and lipid control): glucose and lipid levels will be measured at various time points throughout the study.
Time Frame
18 days
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Diabetic subjects
Age ≥ 18 and ≤ 65 years
Body Mass Index ≤45
Drug naive type 2 diabetes or type 2 diabetes previously treated with an oral antidiabetic drug
Inclusion Criteria: Healthy subjects
Age ≥ 18 and ≤ 65 years
Body Mass Index ≥ 18 and ≤ 29
Good health as determined by medical history, ECG, clinical chemistry, hematology, urinalysis, virology, and a physical examination.
Exclusion Criteria: Diabetic subjects
Have a current or expected requirement for any antidiabetic or lipid-lowering drug
Exclusion Criteria: Healthy subjects
Have, or have had a history of clinically significant neurological, urological, gastrointestinal, renal, hepatic, cardiovascular, psychological, pulmonary, metabolic, endocrine, hematological, or other major disorders including cancer
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Medical Director, MD
Organizational Affiliation
Sumitomo Pharma America, Inc.
Official's Role
Study Director
Facility Information:
Facility Name
Cetero Research
City
San Antonio
State/Province
Texas
ZIP/Postal Code
78229
Country
United States
12. IPD Sharing Statement
Learn more about this trial
Safety, Pharmacokinetics and Pharmacodynamics of DSP-8658 in Patients With Type 2 Diabetes Mellitus and Healthy Adults
We'll reach out to this number within 24 hrs